Donate Toggle Menu

2024 IKCS: Europe

18-20 April, 2024

Hotel Meliá
Sitges, Spain

Important Dates

Review the important dates below for 2024 IKCS: Europe

Abstract Submissions Open!December 14, 2023
Program-At-A-Glance Coming Soon!December 2024
Registration Now OpenNovember 2024
Hotel Reservation InformationNovember 2024
Program Details and Speakers ReleasedJanuary 2024
Abstract Submission Deadline
(all complete Regular, TPS, and Case Report submissions, and all LBA Placeholders due at this time)
February 8, 2024
LBA Submission Deadline (LBA Placeholder required by February 2, 2024, deadline)February 29, 2024, (placeholder required by February 8, 2024)
Abstract Notifications Sent to Lead AuthorsMarch 7, 2024
Early Symposium Registration DeadlineMarch 23, 2024
Abstract Withdrawal Deadline
(Withdrawal requests must be submitted by the Lead Author to [email protected])
March 21, 2024
Abstract Titles ReleasedMarch 28, 2024
Deadline to cancel Hotel Reservations without feesLess than 14 days before the arrival the full cost of the stay will be charged to the credit card provided at time of reservation, as a cancellation cost.
Presentation Slides DueMarch 22, 2024
Poster Uploads DueApril 4, 2024
Full Abstracts Released April 16, 2024 at 16:00 ET
Post-Meeting On Demand AvailableBeginning of May 2024
Meeting DatesApril 18 – 20, 2024
Hotel Cut-off for group rate dateApril 1, 2024

Registration and Hotel Information


CategoryEarly Registration Rate (Register by March 23, 2024 at 23:59 GMT)Regular Registration Rate (After March 23, 2024)Post-Event (April 25, 2024 to December 31, 2024)
In-person Physician/Scientist€415€555N/A
Group In-person Physician/Scientist (this rate includes 1 in-person Physician/Scientist registration and 3 post-meeting on-demand access registrations)€695€830N/A
In-person Allied Health Professional€295€400N/A
In-person Physician In-Training€295€400N/A
In-person Patient/Advocate/Caregiver€50€50N/A
In-person Industry€600€765N/A
In-person MediaComplimentary**Complimentary**N/A
Post-Event On-Demand Access€185€185€185
**If you are looking for a group registration of 3 or more, please contact [email protected]

*If you are a patient, advocate, or caregiver please contact [email protected] with your interest in attending IKCS. This registration category is reserved for patients, advocates, and caregivers who do not meet one of the other registration categories.

**If you are a media employee interested in attending IKCS, please contact [email protected] with your interest and plan for meeting coverage. This registration category is reserved only for media.

Hotel Accommodations

Meeting Venue: Meliá Sitges
Venue Address: Joan Salvat Papasseit, 38, Sitges, 08870 Spain

Booking Policy: Support the KCA and Save with Our Host Hotel!  – Exclusive Benefits for Event Attendees:

Special Room Rates: Enjoy discounted rates when you book your guest room at our host hotel forIKCSEU24. We’ve negotiated rates lower than the standard, ensuring you get the best value for your stay.

Supporting the KCA: By choosing our host hotel, you’re directly contributing to the Kidney Care Association (KCA). Your reservation helps fund patient and healthcare professional programs. The KCA is committed to filling our room block. Unfulfilled rooms become a financial responsibility. Your decision to stay with us ensures resources go where they’re needed most.

Revenue Impact: In the spirit of transparency, we want to emphasize that falling short of our revenue goals affects not only the current event but future ones as well. If we don’t meet our targets, subsequent event registration fees may need adjustments to cover lost revenue.


Abstract Submission Guidelines

Abstract Submission Guidelines

Follow the guidelines below to submit an abstract to IKCS: Europe.

  • All submitters are required to create a free account with Swoogo (our new event platform) to access the abstract submitter.


  • Abstract Submission Deadline (all submissions including LBA placeholder submissions due at this time): February 8, 2024

  • LBA Final Data Submission Deadline (final data, results, and conclusions for LBA placeholder submissions due at this time): February 29, 2024,
    • Additional instructions will be sent to lead authors to complete their LBA submissions by March 14, 2024.
    Abstract Notifications will be sent to lead authors by the week of March 7, 2024


  • Regular Abstract (All research types and summaries of new, ongoing, and updated research relating to kidney cancer will be considered)
  • Trials in Progress Abstract (All research types that are open, enrolling, ongoing, and have not reached pre-specified endpoints for analysis.)
  • Late-breaking Data Submission Abstract (Phase I, II, III, or IV trials and original, high-impact research that could impact practice and standard of care)
  • Case Report (A report of the diagnosis, treatment, and follow up of an individual patient)


  • Abstract Title: The title should objectively describe the study and should not include proprietary drug names.
  • Abstract Text: The abstract text should be no more than 300 words including the title and abstract body. Word count does not apply towards spaces, authors, and affiliations. IKCS does not have a standard format for abstracts. It does not need to be subdivided into Background, phMethods, Results, and Conclusions sections, but any well-written abstract should contain the elements in that basic order.
  • Optional Abstract Graph, Illustration, or Table: One brief graph, illustration, or table is permitted. An image, or table should only be included if you think it will help to clarify a complex methodology or to summarize an involved set of results.
  • Authors: The maximum number of authors permitted is 20.
    • Pharmaceutical industry authors are allowed to present abstracts in non-CME sessions (Poster Sessions). If an abstract is selected for presentation in a CME-session, and the presenter has an EACCME®-defined conflict of interest*, an alternate presenter must be identified. A non-named author can present a poster if written permission is provided by the lead author to [email protected].
    • *Conflict of interest: A set of conditions in which judgment or decisions concerning a primary interest (for example a patients’ welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).
  • Conflict of Interest Disclosure: Presenting authors must submit a Conflict of Interest disclosure identifying financial relationships with ACCME-defined ineligible companies. Co-authors do not need to submit a COI Disclosure.


  • Confidentiality Policy: Abstracts are confidential at the time of submission. KCA will release full abstracts on the meeting platform website April 16, 2024, leading up to the meeting. Meeting registration is required to access the abstracts.
  • Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author.
  • KCJ Open Access Policy
  • Permissions Policy
  • Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author and will not be published/printed by KCA/KCJ.


Following symposia participation, authors may be asked to contribute a concise manuscript for potential inclusion in a dedicated Kidney Cancer publication. Stay tuned for forthcoming details.

Abstract Submission Categories

Abstract Submission Categories

Abstracts in the following categories will be considered for presentation:

  • Basic Science
  • Translational Research
  • Disparities in Cancer, Care and Access
  • Diagnostics
  • Financial Toxicity – Care Delivery/Health Outcomes
  • Imaging
  • Patient-reported Outcomes
  • Post-treatment Surveillance
  • Prevention and Screening
  • Quality of Care and Quality Improvement
  • Real-World Evidence
  • Survivorship
  • Treatment Toxicities and Symptom Management
  • Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.)
  • Therapeutics (Local- Primary and Metastatis)
  • Tumor Biology, Biomarkers, and Pathology
  • Other
Late-breaking Data Submission Guidelines

Late-Breaking Data Submission Guidelines

Abstracts submitted in this category are Phase I-IV trials, or original research that could impact practice and standard of care. LBAs should be studies where results and conclusions are not yet available by the February 8 deadline, but will be available by the February 29, 2024 deadline.

Abstracts submitted in this category must have a placeholder submission (all components except for Results and Conclusions sections) received by the February 8, 2024 abstract submission deadline.

Lead authors will receive separate instructions to complete LBA placeholder submissions by February 15, 2024.

Trials in Progress (TIP) Abstract Submission Guidelines

Trials-In-Progress Abstract Submission Guidelines

Abstracts submitted in this category are ongoing and should not include data, results, nor conclusions.

TIP abstracts are open, enrolling, or ongoing and have not reached any protocol-specific endpoints for analysis, and consequently will only require the completion of the Background and Methods sections.

Abstracts in all phases of clinical research (I, II, III, IV) may be submitted.

TIP Abstracts, if accepted, are eligible for Poster Presentation. TIP abstracts are not eligible for Oral Presentation.

Encore Abstracts

Encore Data

IKCS Meetings seek to highlight cutting edge research; therefore, submissions should reflect unpublished work. Encore Data is still accepted for submission under any of the abstract categories only if a novel aspect of that research is presented. If you feel your work is derivative, but still has novelty merits, highlight this fact and be clear about what advancements you made. The program committee maintains the ultimate discretion to accept or reject encore abstracts. Abstracts presented at past IKCS meetings will not be accepted. 

Abstract Review and Selection Process

Abstract Review and Selection Process

Abstracts will be reviewed by the IKCS: Europe Scientific Planning Committee. Abstract notifications will be sent to lead authors in March 7, 2024,

Merit Awards, Top Abstracts and Outstanding Visual Design Posters

IKCS: Europe 2024 Merit Awards

All award winners will be notified by March 7, 2024. All abstracts submitted will automatically be eligible for a Merit Award.  

Merit Awards are given to abstract authors who submit high-quality abstracts. Winners must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position.

 Merit Award Eligibility Requirements:

  • Submit an abstract  
  • Must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position.
  • Must attend the meeting in person.
  • In addition to the oral presentation, submitters must also produce a poster.

Selection Process:

The IKCS Scientific Planning Committee will select four recipients to receive a merit award for the best original submissions.


All four winners will receive a complimentary registration to IKCS 2024 Europe, be recognized in the program booklet and on stage, and provided a speaking slot during the oral abstract session.

Top Rated Posters

Top rated poster awards are given to the top five posters after Merit Award selection. The organizing committee will select the top five posters. One presenter from each of the five abstracts selected must attend the Symposium to receive the award. Poster Ads Presenters will be selected from all abstracts to prepare a 2-minute PPT presentation (2 slides max) to succinctly showcase and promote the poster on Friday, April 19, 2024 at the IKCSEU24.

 Top Rated Poster Award Eligibility Requirements:

  • Must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position.
  • Must attend the meeting in person.
  • In addition to the oral presentation, submitters must also produce a poster

Selection Process:

The IKCS Scientific Planning Committee will select five recipients to receive a merit award for the best original submissions.


All winners will be recognized in the program booklet, be selected for poster ads on stage (2-min ad to the main conference audience) and will receive a TOP ABSTRACT/POSTER ribbon.

Outstanding Visual Design Poster

Will be assigned on site. Requirements: posters Must be up before 12pm on Friday April 19.

Selection Process:

Planning committee selects on-site before the poster walk.


All Outstanding Visual Design Posters will receive recognition at the symposium.

Abstract Presenter Guidelines (Oral & Poster Presentation Guidelines)

Abstract Presenter Guidelines

All accepted abstracts and lead authors are required to present in-person at 2024 IKCS: Europe in Sitges, Spain. Accepted abstracts will be displayed at the live meeting and electronic versions will be available online.

All Abstract Presenters must register for the conference.

Oral Abstract Presenter Guidelines

  • Presentation Format: Oral Abstract Presenters should prepare a 7-minute PPT presentation.
  • Slide Upload Deadline: PPT slides are due in the presenter portal by March 22, 2024. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
  • Conflict of Interest Disclosure: Oral Abstract Presentations must include in a COI Disclosure slide.
  • Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by March 8, 2024. Requests received after this date cannot be guaranteed removal from the program.
  • Corresponding Poster: Oral Abstract presenters should also prepare a poster presentation to accompany their oral presentation.
  • 1-min Poster ad: Selected abstracts’ presenters are to create a brief, one-minute PowerPoint ad with up to two slides to attract visitors to their poster during the poster session.

Poster Presenter Guidelines

  • Poster Presenters should prepare a PDF and printed poster. Attendees will have the opportunity to visit posters in-person onsite and view electronic versions online.
  • ePoster Deadline: Presenters should upload a PDF poster to the Speaker Portal by April 5th, 2024. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
  • Printed Posters: Poster Presenters should bring a printed poster onsite to hang on an assigned poster board for the duration of the meeting.
  • Size: Printed posters should not exceed 95 cm in height by 97 cm in width. This is the size of the Poster Board. Poster hanging materials will be provided onsite.
  • Printing: Poster Presenters should arrange their own poster printing and carry their poster onsite. If a Poster Presenter is unable to attend in-person, they should arrange for a colleague to carry and present the poster onsite.
  • KCA is not responsible for costs associated with printing and shipping posters.
  • Template: No specific Poster Template is required.
  • Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by March 8, 2024. Requests received after this date cannot be guaranteed removal from the program.
Abstract Release Information

Abstract Release Information

Abstract titles will be released to the media March 28, 2024.

Poster Presentations will become available: April 16, 2024
PDF versions of presentation slides will become available during the specific session for the presentation.

Abstract submission closes February 15, 2024,


Please contact [email protected].

2024 IKCS: Europe Scientific Planning Committee

Thank you to our 2024 IKCS: Europe Planners!


Lars Lund, MD, DMSci
Cristina Suarez, MD, PhD

Committee Members

Ignacio Duran, MD, PhD
Annika Fendler, PhD
Gabriel Malouf, MD, PhD
Lisa Pickering, MD, PhD
Michael Staehler, MD, PhD

Faculty Presentation Guidelines

Faculty Disclosures coming soon!

Speaker PPT Slide Presentations are due in the Faculty/Speaker Portal by March 22, 2024.

Meeting Format

Meeting Format: 2024 IKCS: Europe will be a live event offering in-person participation for meeting attendees. On-demand access will be available post-meeting. Sessions will be recorded, but will not be live-streamed. Faculty are expected to attend in-person in.

Conflict of Interest Disclosure & Session Preparation Information

Conflict of Interest Disclosure: Confirmation of any faculty invitation requires agreement to abide by Conflict of Interest procedures in addition to policies set forth by the Kidney Cancer Association, The France Foundation, and the Accreditation Council for Continuing Medical Education (ACCME) for content and presentation. All Faculty are required to submit a full disclosure of financial interests with commercial entities. All Conflict of Interest Disclosures will be reviewed by The France Foundation for final approval and participation in the program. Failure to submit a Conflict of Interest Disclosure will prohibit participation in the program.

Session Preparation: Speakers should upload their presentation slides by 22 March 2024. Slides will be reviewed by Session Chairs/Moderators and CME regulators to ensure compliance with CME guidelines, minimize content overlap between sessions, and help presentations contribute to a cohesive and educational session. Speakers may receive recommendations for slide adjustments. Speakers who are only able to participate virtually will receive instructions to pre-record their presentations prior to the meeting, along with instructions to participate in the live panel Q+A at the end of the session.

Download the PPT Template– Available January 2024

Faculty Benefits: Faculty may be eligible for benefits including Registration, Hotel accommodation, and travel assistance. Faculty will receive details and instructions for meeting arrangements directly via email. If you have questions please contact [email protected].

Sponsorship and Exhibitor Opportunities